Innovative PET Tracer Enhances Detection of Kidney Cancer

A new positron emission tomography (PET) tracer called 68Ga-RCC78 is showing promise in the detection of clear cell renal cell carcinoma (ccRCC), according to early clinical research presented at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting. This novel tracer targets carbonic anhydrase IX (CAIX), a marker that is overexpressed in ccRCC, providing a significant advantage in identifying cancerous lesions with high sensitivity and superior tumor-to-background contrast.

Historically, developing effective CAIX-targeted radiopharmaceuticals has been challenging due to high physiological expression of CAIX in the gastrointestinal tract, which causes interference in abdominal imaging. However, 68Ga-RCC78, a cyclic peptide-based PET tracer, appears to overcome these limitations. Unlike traditional antibody-based tracers that take longer to clear from the body, 68Ga-RCC78 rapidly achieves high-contrast visualization.

In studies conducted on mice with CAIX-high xenografts, 68Ga-RCC78 demonstrated significant tumor uptake and swift background clearance. Further evaluation in a first-in-human study involving 13 patients with ccRCC confirmed the tracer's efficacy, accurately differentiating between CAIX-positive and CAIX-negative tumors. This is consistent with biopsy immunostaining observations. The tracer's high tumor uptake, coupled with its lower background activity, enhances the visibility of intra-abdominal and metastatic lesions, surpassing the performance seen with the standard 18F-FDG tracer.

"This research provides a more precise molecular map for kidney cancer," stated Dawei Jiang, PhD, from the Nuclear Medicine Department at Wuhan Union Hospital. The tracer not only assists in diagnostic imaging but is also being explored for therapeutic applications by labeling it with isotopes that could deliver targeted radiation therapy.

The development of 68Ga-RCC78 is currently in the early stages of clinical evaluation, with plans for wider clinical trials and potential broader availability over the next few years, pending further regulatory approvals.

This advancement in molecular imaging technology holds potential for significant improvements in the detection and treatment of kidney cancer, particularly ccRCC, offering a tailored approach that combines diagnostic and therapeutic benefits.